The exact text we saved

This is the version exactly as it was saved, character for character. The SHA-256 hash below is a 64-character code worked out from that text. Run the same text through SHA-256 and you get the same code; change a single letter and the code comes out completely different. Each version also stores the previous version’s hash, which chains them together so no version can be swapped out quietly.

TRUVACE RECORD VERSION
record: TRV-2026-1173
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-09-23T06:53:29.382477Z
status: published
lens: p_space
sector: health
headline: AI-Driven precision targeted therapy for EGFR-mutant non-small cell lung cancer: From therapeutic evolution and resistance mechanisms to intelligent decision systems
dek: ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision…
gain_title: (none)
problem_title: ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision oncology." Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup).
trace_subject: (none)
gain_reading: (none)
gain_evidence: (none)
problem_reading: ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision oncology." Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup).
problem_evidence: (none)
quick_read: ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision oncology." Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup). We also critically evaluate artificial intelligence's translational potential in molecular subtyping, resistance prediction, and drug discovery, alongside the data, modeling, and validation barriers limiting its clinical deployment.ConclusionsDespite the expanding therapeutic armamentarium, clinically meaningful precision remains constrained by persistent misconceptions and translational bottlenecks.

Artificial intelligence (AI) offers enabling potential, but its integration requires standardized data infrastructures, dynamic modeling, and prospective validation. AI outputs should currently be interpreted as hypothesis-generating tools, not replacements for clinical judgment.
limitation: 
tag: Evidence-backed problem
key_points: We also critically evaluate artificial intelligence's translational potential in molecular subtyping, resistance prediction, and drug discovery, alongside the data, modeling, and validation barriers limiting its clinical deployment.ConclusionsDespite the expanding therapeutic armamentarium, clinically meaningful precision remains constrained by persistent misconceptions and translational bottlenecks. | Artificial intelligence (AI) offers enabling potential, but its integration requires standardized data infrastructures, dynamic modeling, and prospective validation. | AI outputs should currently be interpreted as hypothesis-generating tools, not replacements for clinical judgment.
rundown: ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision oncology." Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup). We also critically evaluate artificial intelligence's translational potential in molecular subtyping, resistance prediction, and drug discovery, alongside the data, modeling, and validation barriers limiting its clinical deployment.ConclusionsDespite the expanding therapeutic armamentarium, clinically meaningful precision remains constrained by persistent misconceptions and translational bottlenecks.

Artificial intelligence (AI) offers enabling potential, but its integration requires standardized data infrastructures, dynamic modeling, and prospective validation. AI outputs should currently be interpreted as hypothesis-generating tools, not replacements for clinical judgment.
sources:
- peer_reviewed | Journal of Oncology Pharmacy Practice | https://doi.org/10.1177/10781552261488860 | 2026-09-22
prev: 0000000000000000000000000000000000000000000000000000000000000000

SHA-256 hash

23e64fdc02080eef3ef3e1a060a75c0f32de30fb4673b35f692b62a764a0fd6c

Previous version’s hash

0000000000000000000000000000000000000000000000000000000000000000